1 2 3 4 5 6

читать далее ... tion 1998 98 2513-2519 3 Heart Protection Study (HPS) Collaborative Group MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatm in 5963 people with diabetes a randomized placebo-controlled trial Lancet 2003 361 2005-2016 4 Watts G F Playford D A Dyslipoproteinemia and hyperoxidafive stress in pathogenesis of endothelial dysfunction in non-insulin-dependent diabetes mellrtus an hypothesis Atherosclerosis 1998 141(1) 17-30 5 Sheu WH Juang В L Lee WJ Endothelial dysfunction is not reversed by simvastatm treatment in type 2 diabetic patients with hypercholesterolemia Diabetes Care 1999 22 1224-1225 6 vanVenrooii F V van de flee M A Bots ML etal Agressive lipid lowering does not improve endothelial function in type 2 diabetes the Diabetes Atorvastatin Lipid Intervention (DALI) Study a randomized, double-blind, placebo-controlled trial Diabetes Care 2002 25 1211-1216 7 European guidelines in cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of eight societies and by invited experts) Eur Heart J 2003 24 1601-1610 8 Fnedwald W Т Levy R J Fredncson D S Estimation of the low density lipoprotein cholesterol in plasma without use of the preparative ultracentnfuge Clin Chem 1972 256 2835-2838 9 LaufsU La Fata V PlutzkyJ LiaoJ Upregulation of endothelial nitric oxide syntfiase by HMG-CoA reductase inhibitors Circulation 1998 97 1125-1135 10 BonettiPO WilsonSH Rodnquez-Porcel M etal Simvastatm preserves myocardial perfusion and coronary microvascular permeability in experimental hypercholesterolemia independent of lipid lowering J Am Coil Cardiol 2002 40 546-554 11 Williams J К Sukhova G К Hernngton DM etal Pravastatm has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys J Am Coil Cardiol 1998 31 684-691 12 Laufs U La Fata VL, Llao JK Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase J б/о/ Chem 1997 272 31725-31729 13 Kureishi Y Luo Z Shioiima I et al The HMG-CoA reductase inhibitors simvastatm activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals Nat Med 2000 6 1004-1010 14 FeronO DessyC DesagerJP etal Hydroxy-niethylglutarylcoenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolm abundance Circulation 2001 103 113-118 15 ScaliaR GooszenME Jones SP etal Simvastatm exerts both anti-inflammatory and cardioprotectwe effects in apolipoprotein E deficient mice Circulation 2001, 103 2598-2603 16 Wagner AH KohlerT RuckschlossU etal Improvement of nitric oxide-dependent vasodilation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide amon formation Artenoscler Thromb Vase В/о/ 2000 20 61-69 17 Sparrow С H BurtonCA Hernandez M etal Simvastatm has anti-inflammatoИсточник: Карпов Р.С. и др. Русский медицинский журнал. 2005. Т.13. №26. С.1727-1730